FR136706

structure in first source

Also Known As:

2-(4-((S)-1-((S)-2-((RS)-3,3,3-trifluoro-1-isopropyl-2-oxopropyl)aminocarbonyl)pyrrolidin-1-yl-)carbonyl-2-methylpropyl)aminocarbonyl benzoylamino acetic acid

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - FR136706: 1

Experts

1.	Hijikawa, Takeshi: 1 article (03/2008)
2.	Ishizaki, Morihiko: 1 article (03/2008)
3.	Kaibori, Masaki: 1 article (03/2008)
4.	Kamiyama, Yasuo: 1 article (03/2008)
5.	Kwon, A-Hon: 1 article (03/2008)
6.	Matsui, Kosuke: 1 article (03/2008)
7.	Okumura, Tadayoshi: 1 article (03/2008)
8.	Ozaki, Takashi: 1 article (03/2008)
9.	Tanaka, Hironori: 1 article (03/2008)
10.	Tokuhara, Katsuji: 1 article (03/2008)

Related Diseases

Acute Liver Failure (Fulminant Hepatic Failure)

03/01/2008 - "Protective effect of neutrophil elastase inhibitor (FR136706) in lethal acute liver failure induced by D-galactosamine and lipopolysaccharide in rats."
03/01/2008 - "These results indicate that NE inhibitor, FR136706, inhibits the induction of a variety of inflammatory mediators such as cytokines, chemokines, and nitric oxide, in part through the inhibition of nuclear factor-kappa B activation, resulting in the prevention of fulminant liver failure."

Related Drugs and Biologics

1.	Secretory Proteinase Inhibitory Proteins
2.	Chemokines
3.	NF-kappa B (NF-kB)
4.	Cytokines
5.	Nitric Oxide (Nitrogen Monoxide)
6.	Lipopolysaccharides
7.	Galactosamine